Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension

Published on 2025-05-23 at 15:23

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Liquidia Corporation

Liquidia Insider Sold Shares Worth $289,199, According to a Recent SEC Filing	07-15	MT
Liquidia Insider Sold Shares Worth $289,199, According to a Recent SEC Filing	07-15	MT
Liquidia Corporation Appoints Dana Boyle as Chief Accounting Officer, Effective July 1, 2025	07-01	CI
BTIG Cuts Price Target on Liquidia to $40 From $45, Maintains Buy Rating	06-27	MT
Liquidia Gets $50 Million From Healthcare Royalty	06-23	MT
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	06-10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	06-10	MT
Liquidia Corporation Schedules First Commercial Shipment of Yutpia (Treprostinil) Inhalation Powder for Patients with Pah and Ph-Ild	06-02	CI
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Liquidia Corporation Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM	05-29
Jefferies Lifts Liquidia Technologies' Price Target to $31 From $27, Buy Rating Kept	05-27	MT
Liquidia Corporation - Special Call	05-27
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
U.S. FDA Approves Liquidia Corporation's YUTREPIA (Treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease	05-23	CI
Oppenheimer Downgrades Liquidia to Underperform From Perform, Price Target is $13	05-19	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
Liquidia Corporation, Q1 2025 Earnings Call, May 08, 2025	05-08
Liquidia Shares Fall After Q1 Net Loss Widens, Revenue Trails Analyst Estimates	05-08	MT
Liquidia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	05-08	CI
Earnings Flash (LQDA) Liquidia Posts Q1 Net Loss $0.45 a Share, vs. FactSet Est of $0.39 Loss	05-08	MT
Earnings Flash (LQDA) LIQUIDIA CORPORATION Reports Q1 Revenue $3.1M, vs. FactSet Est of $3.3M	05-08	MT
Liquidia Corp Unit Files Patent Infringement Action Against United Therapeutics	04-22	RE
Liquidia Corporation Presents at 24th Annual Needham Virtual Healthcare Conference, Apr-08-2025 08:45 AM	04-08